Implications of human induced pluripotent stem cells in metabolic disorders: from drug discovery toward precision medicine

被引：13
|
作者：
Cota-Coronado, Agustin [1 ]
Berenice Ramirez-Rodriguez, P. [2 ]
Padilla-Camberosl, Eduardo [1 ]
Diaz, eNstor F. [2 ]
Flores-Fernandez, Jose M. [3 ,4 ]
Avila-Gonzalez, Daniela [1 ,2 ]
Emmanuel Diaz-Martinez, N. [1 ]
机构：
[1] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Biotecnol Med & Farmaceut, Guadalajara, Mexico
[2] Inst Nacl Perinatol, Dept Fisiol & Desarrollo Celular, Ciudad De Mexico, Mexico
[3] Univ Alberta, Dept Biochem, 474 Med Sci Bldg, Edmonton, AB T6G 2R3, Canada
[4] Tecnol Estudios Super Villa Guerrero, Div Ingn Ind Alimentarias & Innovac Agr Sustentab, Carretera Toluca Ixtapan Sal,Km 64-5, Villa Guerrero 61763, Estado De Mexic, Mexico
来源：
DRUG DISCOVERY TODAY | 2019年 / 24卷 / 01期
关键词：
INSULIN-PRODUCING CELLS; ENDOTHELIAL-CELLS; GENE CORRECTION; BETA-CELLS; GENERATION; LIVER; ADULT; DIFFERENTIATION; INDUCTION; THERAPY;
D O I：
10.1016/j.drudis.2018.10.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Human induced pluripotent stem cells (hiPSCs) enable in vitro high-throughput pharmacological screening assays of diseased tissue. Together with recent genome-wide association studies (GWAS), hiPSCs enable the identification of key mutations for the development of effective treatments based on precise drugs. In concert with CRISPR/Cas9 systems, hiPSC technology can reveal therapeutic targets in metabolic disorders. The ex vivo CRISPR correction of autologous patient-derived hiPSCs has led to the development of replacement cell therapies, providing better patient prognoses.
引用
收藏
页码：334 / 341
页数：8
相关论文
共 50 条
  • [21] The updated view on induced pluripotent stem cells for cardiovascular precision medicine
    Wang, Yong
    Lei, Wei
    Yang, Jingsi
    Ni, Xuan
    Ye, Lingqun
    Shen, Zhenya
    Hu, Shijun
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2021, 473 (07): : 1137 - 1149
  • [22] Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine
    Novelli, Giuseppe
    Spitalieri, Paola
    Murdocca, Michela
    Centanini, Eleonora
    Sangiuolo, Federica
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 10
  • [23] Cardiomyocytes from human pluripotent stem cells in safety pharmacology, drug discovery and disease
    Mummery, Christine
    HUMAN GENE THERAPY, 2013, 24 (05) : A8 - A8
  • [24] Human Induced Pluripotent Stem Cells: Now Open to Discovery
    Durak, Omer
    Tsai, Li-Huei
    CELL STEM CELL, 2014, 15 (01) : 4 - 7
  • [25] How induced pluripotent stem cells are informing drug discovery in psychiatry
    Sun, Yishan
    Dolmetsch, Ricardo E.
    SWISS MEDICAL WEEKLY, 2016, 146 : w14241
  • [26] Converging technologies to enable induced pluripotent stem cells in drug discovery
    Flynn, Peter
    Yingling, Jessica
    Shoemaker, Dan
    REGENERATIVE MEDICINE, 2010, 5 (04) : 489 - 491
  • [27] Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
    Beghini, Daniela Gois
    Kasai-Brunswick, Tais Hanae
    Henriques-Pons, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [28] Induced pluripotent stem cells — opportunities for disease modelling and drug discovery
    Marica Grskovic
    Ashkan Javaherian
    Berta Strulovici
    George Q. Daley
    Nature Reviews Drug Discovery, 2011, 10 : 915 - 929
  • [29] Induced pluripotent stem cells - opportunities for disease modelling and drug discovery
    Grskovic, Marica
    Javaherian, Ashkan
    Strulovici, Berta
    Daley, George Q.
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (12) : 915 - 929
  • [30] Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine
    Ziwei Pan
    Antje Ebert
    Ping Liang
    Pflügers Archiv - European Journal of Physiology, 2021, 473 : 1151 - 1165
12345